消癥散积Ⅰ号方治疗湿郁血瘀型非酒精性脂肪性肝病的临床研究

消癥散积Ⅰ号方治疗湿郁血瘀型非酒精性脂肪性肝病的临床研究摘要：

目的：探讨消癥散积Ⅰ号方治疗湿郁血瘀型非酒精性脂肪性肝病（NAFLD）的临床疗效和安全性。

方法：选择2017年1月至2019年12月在我院住院治疗的NAFLD患者114例，将其随机分为治疗组和对照组，每组57例。治疗组口服消癥散积Ⅰ号方，对照组口服复方左旋肉碱，均为每日口服一次，每次1.8g，连续治疗12周。观察两组患者治疗前后体重、肝功能、血脂、胰岛素抵抗指数（HOMA-IR）等指标的变化，并比较两组疗效和安全性。

结果：治疗组患者治疗后体重、甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）及HOMA-IR指数均显著下降，高密度脂蛋白胆固醇（HDL-C）升高，且与对照组比较差异有统计学意义（均P<0.05）。治疗组患者的总有效率为89.47%，对照组为75.44%，差异有统计学意义（P<0.05）。两组患者均未出现不良反应。

结论：消癥散积Ⅰ号方治疗湿郁血瘀型NAFLD具有较好的疗效和安全性，值得临床推广应用。

关键词：消癥散积Ⅰ号方；非酒精性脂肪性肝病；湿郁血瘀型；疗效；安全性

Abstract：

Objective:ToinvestigatetheclinicalefficacyandsafetyofXiaozhenSanjiIformulainthetreatmentofdampnessstagnationandbloodstasistypenonalcoholicfattyliverdisease(NAFLD).

Methods:Atotalof114NAFLDpatientswhowerehospitalizedfortreatmentfromJanuary2017toDecember2019wererandomlydividedintoatreatmentgroupandacontrolgroup,with57casesineachgroup.ThetreatmentgroupwasgivenXiaozhenSanjiIformula,andthecontrolgroupwasgivenlevocarnitine,bothofwhichweretakenorallyonceadayatadoseof1.8geachtimefor12consecutiveweeks.Thechangesinweight,liverfunction,bloodlipids,andinsulinresistanceindex(HOMA-IR)beforeandaftertreatmentwereobservedinbothgroups,andtheefficacyandsafetyofbothgroupswerecompared.

Results:Aftertreatment,theweight,triglycerides(TG),totalcholesterol(TC),low-densitylipoproteincholesterol(LDL-C),andHOMA-IRindexinthetreatmentgroupweresignificantlydecreased,andhigh-densitylipoproteincholesterol(HDL-C)wassignificantlyincreased,andthedifferencescomparedwiththecontrolgroupwerestatisticallysignificant(P<0.05).Thetotaleffectiverateofthetreatmentgroupwas89.47%,whichwassignificantlyhigherthanthatofthecontrolgroup(75.44%,P<0.05).Noadversereactionswereobservedinbothgroups.

Conclusion:XiaozhenSanjiIformulahasgoodefficacyandsafetyinthetreatmentofdampnessstagnationandbloodstasistypeNAFLD,andisworthyofclinicalpromotionandapplication.

Keywords:XiaozhenSanjiIformula;nonalcoholicfattyliverdisease;dampnessstagnationandbloodstasistype;efficacy;safet。Nonalcoholicfattyliverdisease(NAFLD)hasbecomeamajorpublichealthissueworldwide,anditsprevalenceisincreasing.ItisimportanttofindeffectiveandsafetreatmentoptionsforNAFLD,especiallyforpatientswithdampnessstagnationandbloodstasistypeNAFLD.Inthisstudy,weevaluatedtheefficacyandsafetyoftheXiaozhenSanjiIformulaforthetreatmentofthistypeofNAFLD.

OurresultsshowedthattheXiaozhenSanjiIformulahadasignificanteffectonimprovingtheliverfunction,lipidmetabolism,andinflammationinpatientswithdampnessstagnationandbloodstasistypeNAFLD.After12weeksoftreatment,thetotaleffectiverateofthetreatmentgroupwassignificantlyhigherthanthatofthecontrolgroup(P<0.05).

TheXiaozhenSanjiIformulaisatraditionalChineseherbalmedicineformulathathasbeenusedformanyyearsinChinatotreatliverdiseases.Itconsistsofseveralherbs,includingRadixPaeoniaeAlba,SemenPersicae,andRhizomaAtractylodisMacrocephalae,whichhavebeenshowntohavepharmacologicaleffectsontheliver,lipidmetabolism,andinflammation.

Ourstudyhassomelimitations,includingasmallsamplesizeandashortfollow-upperiod.Therefore,furtherstudieswithlargersamplesizesandlongerfollow-upperiodsareneededtoconfirmtheefficacyandsafetyoftheXiaozhenSanjiIformulainthetreatmentofdampnessstagnationandbloodstasistypeNAFLD.

Inconclusion,ourstudysuggeststhattheXiaozhenSanjiIformulaisaneffectiveandsafetreatmentoptionforpatientswithdampnessstagnationandbloodstasistypeNAFLD.IthasthepotentialtobewidelyusedinclinicalpracticeasacomplementarytherapyforNAFLD。Non-alcoholicfattyliverdisease(NAFLD)hasbecomeaglobalhealthconcernduetotheincreasingprevalenceandpotentialliver-relatedcomplicationsassociatedwiththecondition.ThetraditionalChinesemedicine(TCM)formulaXiaozhenSanjiIhasbeenusedtotreatNAFLDinChina,buttheefficacyandsafetyoftheformulahavenotbeenwidelystudied.

Basedontheavailableevidence,itcanbeconcludedthatXiaozhenSanjiIisaneffectiveandsafetherapyforpatientswithdampnessstagnationandbloodstasistypeNAFLD.TheformulahasthepotentialtobecomeanimportantcomplementarytherapyinthemanagementofNAFLD,especiallyforpatientswhodonotrespondwelltoconventionaltreatmentoptions.

However,morestudieswithlargersamplesizesandlongerfollow-upperiodsareneededtofullyunderstandtheefficacyandsafetyofXiaozhenSanjiI.Additionally,futurestudiesshouldalsofocusontheunderlyingmechanismsofactionoftheformulaandtheoptimaldosageanddurationoftreatment.

Overall,TCMformulassuchasXiaozhenSanjiIofferapromisingalternativetoconventionaltreatmentsforNAFLD.ByincorporatingTCMtherapiesintoconventionaltreatmentplans,healthcareproviderscanprovideholisticandpersonalizedcareforpatientswithNAFLD,leadingtobetterhealthoutcomesandqualityoflife。InadditiontoTCMformulas,othertraditionaltherapiessuchasacupunctureandmoxibustionhavealsoshownpromiseinthetreatmentofNAFLD.Thesetherapieshavebeenfoundtoimproveliverfunction,reduceinflammation,andincreaseinsulinsensitivity,amongotherbenefits.

Acupunctureinvolvestheinsertionoffineneedlesintospecificpointsonthebodytostimulatehealingandimprovefunction.Studieshaveshownthatacupuncturecanreduceliverenzymes,improveinsulinsensitivity,andreduceinflammationinpatientswithNAFLD.Moxibustion,whichinvolvestheburningoftheherbmugwortonspecificacupuncturepoints,hasalsobeenfoundtoimproveliverfunctionandreduceinflammation.

Combinedwithlifestylemodificationssuchasdietarychanges,exercise,andstressreduction,TCMtherapiesandtraditionaltherapieslikeacupunctureandmoxibustioncanprovideacomprehensiveapproachtothetreatmentofNAFLD.Thisintegratedapproachcanimproveliverfunction,reduceinflammation,andimproveoverallhealthoutcomesforpatientswithNAFLD.

Inconclusion,theincreasingprevalenceofNAFLDrepresentsasignificanthealthchallengeworldwide.Whileconventionaltreatmentsfocusprimarilyonlifestylemodificationsandmedicationstocontrolsymptoms,TCMtherapiesofferapromisingalternativeforpatientswithNAFLD.VariousTCMformulasandtraditionaltherapieslikeacupunctureandmoxibustionhavebeenshowntoimproveliverfunction,reduceinflammation,andprovideotherbenefits.Futureresearchshouldcontinuetoexploretheefficacyandunderlyingmechanismsofthesetherapies,aswellasoptimaldosageanddurationoftreatment.ByincorporatingTCMtherapiesintoconventionaltreatmentplans,healthcareproviderscanprovideholisticandpersonalizedcareforpatientswithNAFLD,leadingtobetterhealthoutcomesandqualityoflife。InadditiontoTCMtherapies,lifestylechangesplayacrucialroleinthemanagementofNAFLD.Obesity,insulinresistance,andhighbloodpressureareallassociatedwithanincreasedriskofdevelopingNAFLD,andaddressingtheseunderlyingconditionscanimproveliverhealth.Weightloss,throughacombinationofdietandexercise,hasbeenshowntoimproveliverfunctionandreduceinflammationinpatientswithNAFLD.Alow-carbohydrate,high-proteindiethasbeenfoundtobeparticularlyeffective,asitstabilizesbloodsugarlevelsandpromotesfatburning.

RegularphysicalactivityisalsoimportantinthemanagementofNAFLD,asitimprovesinsulinsensitivityandpromotesweightloss.ForpatientswithNAFLD,acombinationofbothaerobicandresistancetrainingisrecommended.Exercisehasbeenshowntoimproveliverfunction,reduceinflammation,andimproveoverallqualityoflifeinpatientswithNAFLD.

Inconclusion,NAFLDisacomplexandmultifactorialdiseasethatrequiresaholisticapproachtomanagement.TheincorporationofTCMtherapies,suchasacupunctureandmoxibustion,intoconventionaltreatmentplanscanprovidepatientsw